{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:28Z","timestamp":1761870508581,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.3816\/clml.2010.n.064","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T23:44:49Z","timestamp":1289432689000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Annual Meeting of the American Society of Clinical Oncology, June 4\u20138, 2010; Chicago, IL"],"prefix":"10.3816","volume":"10","author":[{"given":"Sonia","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarati","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.064_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.seminhematol.2010.01.003","article-title":"Rituximab in indolent lymphomas","volume":"47","author":"Sousou","year":"2010","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.064_bib2","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.064_bib3","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"Van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib4","first-page":"574s","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy","volume":"28","author":"Pettengell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/jnci\/djp255","article-title":"Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Landgren","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLML.2010.n.064_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLML.2010.n.064_bib7","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib8","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib9","first-page":"574s","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib10","first-page":"442s","article-title":"First results of long-term rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35\/03","volume":"27","author":"Taverna","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib11","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.064_bib12","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.064_bib13","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.6004\/jnccn.2010.0113","article-title":"The role of maintenance therapy in the treatment of multiple myeloma","volume":"8","author":"Badros","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.3816\/CLML.2010.n.064_bib14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib15","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib16","first-page":"577s","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104","volume":"28","author":"McCarthy","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib17","first-page":"577s","article-title":"Lenalidomide maintenance after transplantation for myeloma","volume":"28","author":"Attal","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cncr.24928","article-title":"Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.064_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.064_bib20","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.064_bib21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.3816\/CLML.2010.n.064_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.3816\/CLML.2010.n.064_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3234.3234","article-title":"Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study","volume":"112","author":"Giles","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.064_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3238.3238","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.064_bib25","doi-asserted-by":"crossref","unstructured":"Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med; 362:2251\u20139.","DOI":"10.1056\/NEJMoa0912614"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib26","first-page":"487s","article-title":"Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year","volume":"28","author":"Larson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib27","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.064_bib29","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cncr.24928","article-title":"Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.064_bib30","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.064_bib31","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS)","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.064_bib32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.064_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib34","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib35","first-page":"487s","article-title":"Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): twelve-month efficacy and safety from the phase III DASISION study","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib36","doi-asserted-by":"crossref","unstructured":"Gallamini A. Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica; 95:1046-8.","DOI":"10.3324\/haematol.2010.024885"},{"key":"10.3816\/CLML.2010.n.064_bib37","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00259-008-0840-z","article-title":"Improving outcome after positive interim PET in advanced Hodgkin's disease: reality vs expectation","volume":"35","author":"Ziakas","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3816\/CLML.2010.n.064_bib38","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib39","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/07357900600981380","article-title":"Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?","volume":"24","author":"Diehl","year":"2006","journal-title":"Cancer Invest"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib40","first-page":"444s","volume":"27","author":"Diehl","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.064_bib41","first-page":"574s","article-title":"Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD","volume":"28","author":"Fiorri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.064_bib42","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3109\/10428190903308056","article-title":"Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation\u2013where do we stand?","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011701975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011701975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:35Z","timestamp":1761870215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011701975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S2152265011701975"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.064","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Annual Meeting of the American Society of Clinical Oncology, June 4\u20138, 2010; Chicago, IL","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010  Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}